Health Canada Approves Tudorza Genuair as a New Treatment for Patients Living With COPD

November 1, 2013
Almirall Canada announced the Health Canada approval of Tudorza Genuair as a long-term maintenance bronchodilator treatment in patients with COPD, including chronic bronchitis and emphysema, giving the 750,000 Canadians living with this serious lung disease a new treatment proven to improve breathlessness, lung function and health-related quality of life.
FirstWord MedTech